# ACRO BIOMEDICAL CO., LTD. (ACBM) · Edgar & Edgarette company card

> Acro Biomedical Co. (ACBM) reported revenue of $0 million in FY2025, operating margin null against a 1.6% median for amusement & recreation services, equity -2745% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1622996 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ACBM) · [JSON](https://www.pops4.com/boards/company/ACBM.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$196,302 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $4,098 |
| Long-term debt | — |
| Total assets | $14,098 |
| Total equity | −$386,964 |
| Equity ÷ assets | -2744.8% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7829.62 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$196K in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity -2744.8% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Against peers (10 filers, $50M+ revenue, services-amusement & recreation services): operating margin null against a 1.6% median.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-01-08 ([filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426000053/0001640334-26-000053-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426001447/0001640334-26-001447-index.htm))

## Recent filings

- 8-K · filed 2026-09-02 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426001447/0001640334-26-001447-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426001345/0001640334-26-001345-index.htm)
- 10-Q · filed 2026-05-05 · [filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426000824/0001640334-26-000824-index.htm)
- 10-K · filed 2026-02-11 · [filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426000241/0001640334-26-000241-index.htm)
- 8-K · filed 2026-01-08 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033426000053/0001640334-26-000053-index.htm)
- 10-Q · filed 2025-11-10 · [filing](https://www.sec.gov/Archives/edgar/data/1622996/000164033425001999/0001640334-25-001999-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001622996.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1622996

## Cite

POPS4, Edgar & Edgarette: ACRO BIOMEDICAL CO., LTD. (ACBM) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ACBM. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.